Atossa Genetics (id:5659 ATOS)
1.22 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:45:43 AM)
Exchange closed, opens in 1 day 22 hours
2.52 USD (2.52%)
-6.87 USD (-6.87%)
-14.08 USD (-14.08%)
-20.26 USD (-20.26%)
56.41 USD (56.41%)
-12.23 USD (-12.23%)
-99.28 USD (-99.28%)
-99.85 USD (-99.85%)
About Atossa Genetics
Market Capitalization 161.03M
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
| Headquarters (address) |
107 Spring Street Seattle 98104 WA United States |
| Phone | 206 588 0256 |
| Website | https://www.atossatherapeutics.com |
| Employees | 12 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ATOS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.700 - 2.31 |
| Market Capitalization | 161.03M |
| P/E trailing | -5.08 |
| P/E forward | -4.74 |
| Price/Book | 2.18 |
| Beta | 1.23 |
| EPS | -0.210 |
| EPS United States (ID:6, base:3400) | 24.26 |